Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Pönisch W, Behre G, Niederwieser D, Lange T. Hebenstreit K, et al. Among authors: leiblein s. Leuk Lymphoma. 2014 Jun;55(6):1274-80. doi: 10.3109/10428194.2013.836598. Epub 2013 Oct 3. Leuk Lymphoma. 2014. PMID: 23964650
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: leiblein s. Am J Hematol. 2017 Apr;92(4):388-396. doi: 10.1002/ajh.24663. Epub 2017 Feb 21. Am J Hematol. 2017. PMID: 28133783 Free article.
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D. Lange T, et al. Among authors: leiblein s. Leukemia. 2004 Sep;18(9):1468-75. doi: 10.1038/sj.leu.2403425. Leukemia. 2004. PMID: 15241437
Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D. Lange T, et al. Among authors: leiblein s. Leukemia. 2011 Mar;25(3):498-505. doi: 10.1038/leu.2010.283. Epub 2010 Dec 7. Leukemia. 2011. PMID: 21135860
Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?
Eisfeld AK, Westerman M, Krahl R, Leiblein S, Liebert UG, Hehme M, Teupser D, Niederwieser D, Al-Ali HK. Eisfeld AK, et al. Among authors: leiblein s. Adv Hematol. 2011;2011:491058. doi: 10.1155/2011/491058. Epub 2011 May 5. Adv Hematol. 2011. PMID: 21687645 Free PMC article.
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D. Poenisch W, et al. Among authors: leiblein s. J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15. J Cancer Res Clin Oncol. 2015. PMID: 25976868
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Pönisch W. Tessenow H, et al. Among authors: leiblein s. J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22. J Cancer Res Clin Oncol. 2017. PMID: 28534173
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39).
Vucinic V, Jentzsch M, Leiblein S, Bach E, Remane Y, Schulze-Forster K, Cross M, Pönisch W, Schwind S, Franke GN, Platzbecker U, Niederwieser D. Vucinic V, et al. Among authors: leiblein s. Transfusion. 2022 Jan;62(1):157-164. doi: 10.1111/trf.16761. Epub 2021 Dec 10. Transfusion. 2022. PMID: 34893987 Clinical Trial.
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.
Hell S, Jentzsch M, Franke GN, Jäkel N, Schulze S, Edelmann J, Nenoff K, Grieb N, Jeremic V, Cross M, Leiblein S, Bach E, Pönisch W, Al-Ali HK, Schwind S, Platzbecker U, Lange T, Niederwieser D, Vucinic V. Hell S, et al. Among authors: leiblein s. Bone Marrow Transplant. 2022 May;57(5):824-826. doi: 10.1038/s41409-022-01609-6. Epub 2022 Feb 18. Bone Marrow Transplant. 2022. PMID: 35181744 Free PMC article. Clinical Trial. No abstract available.
37 results